Clinical trials: Hepatitis C, completed
Hepatitis C, Chronic
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants with varying degrees of hepatic…
- Trial name
- NCT01919125
- Testing
- IDX719
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HEPATITIS C, Virus, Human Immunodeficiency
Antiviral Pharmacology and Adherence in Drug Users
Approximately one half of all Americans living with Hepatitis C virus (HCV) are drug users, yet they are the least likely to receive HCV treatment.
- Trial name
- NCT02573376
- Testing
- Directly Observed Therapy, Wirelessly Observed Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Colorado, Denver
Hepatitis C Virus-infected Cirrhosis
A Follow-up Evaluation Study of PRI-724-1101
The purpose of this study To evaluate the safety and efficacy of PRI-724 administration in patients with cirrhosis due to hepatitis C by 12-month follow-up.
- Trial name
- NCT02828254
- Testing
- PRI-724
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Komagome Hospital
Hepatitis C Virus, HCV Infection
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection
Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream.
- Conditions
- Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
- Trial name
- NCT01091077
- Testing
- Naringenin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3…
- Trial name
- NCT02652377
- Testing
- EDP-494
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer…
- Trial name
- NCT02868242
- Testing
- LDV/SOF
- Where
- Egypt
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Disease
Short Course of Interferon Treatment in Patients With HCV Infection
To determine if a shorter course of interferon and ribavirin therapy will be sufficient in carefully selected patients with chronic hepatitis C virus genotype 3 infection, as compared to the standard length of treatment of 6…
- Conditions
- Hepatitis C, Chronic Disease, Treatment
- Trial name
- STAR (NCT00502970)
- Testing
- 16 weeks Interferon Tiw with Ribavirin, 24 weeks Interferon
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Aga Khan University
Hepatitis C, Chronic
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
This 4 arm study is designed for patients with CHC who have not responded to peginterferon alfa-2b (12KD)/ribavirin combination therapy.
- Trial name
- NCT00087646
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject.
- Trial name
- NCT01718145
- Testing
- Daclatasvir, Asunaprevir, Ribavirin
- Where
- 48 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection, Response to Therapy of
Rapid HCV Treatment Access for Persons Who Use Drugs
This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP).
- Trial name
- RAPID-HCV (NCT04677153)
- Testing
- Test and treat plus peer mentors, Usual care
- Where
- 4 sites in United States, Canada
- Volunteers
- 198 people
- Sponsor
- Johns Hopkins University
Hepatitis C, Chronic
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
This multi-center, prospective observational study will evaluate the correlation of liver biopsy and transient elastography in liver fibrosis assessment in patients with chronic hepatitis C. Data will be collected for 96 weeks.
- Trial name
- NCT01671046
- Where
- 10 sites in Brazil
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure
The purpose of this study is to describe the management of patients with chronic hepatitis C and previous treatment failure.
- Trial name
- NCT01033045
- Where
- 104 sites in Spain
- Volunteers
- 2,178 people
- Sponsor
- Fundacion IMIM
Chronic Hepatitis C
Gamma Interferon Therapy for Chronic Hepatitis C
This study will test whether gamma interferon is effective in treating chronic hepatitis C infection-a long-lasting viral infection affecting the liver.
- Trial name
- NCT00028275
- Testing
- Gamma Interferon 1b
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis c
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on…
- Trial name
- NCT00926614
- Testing
- pioglitazone (Actos), atorvastatin (Lipitor)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brooke Army Medical Center
Chronic Hepatitis C
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Background: Chronic hepatitis C is a serious liver disease. Current treatments have side effects. New drugs have been developed, but they work better in some people than others. Researchers want to learn why.
- Trial name
- NCT02468648
- Testing
- Sofosbuvir, GS-5816
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C
The DETECT HCV Screening Trial
The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency…
- Trial name
- DETECT HCV (NCT04003454)
- Testing
- HCV Screening
- Where
- 3 sites in United States
- Volunteers
- 147,533 people
- Sponsor
- Denver Health and Hospital Authority
Hepatitis C, Hemophilia
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection.
- Trial name
- NCT00707772
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 400 people
- Sponsor
- Baqiyatallah Medical Sciences University
HIV, Hepatitis C
DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs
The overarching purpose of the proposed research is to demonstrate that high coverage implementation of combined prevention and care using an innovative approach will end the HIV epidemic among PWID in Haiphong, Viet Nam.
- Conditions
- HIV, Hepatitis C, Mental Health
- Trial name
- DRIVE (NCT03526939)
- Where
- Vietnam
- Volunteers
- 5,546 people
- Sponsor
- New York University
Hepatitis C
EBR/GZR for HCV-1b Patients Receiving Hemodialysis
Hepatitis C virus (HCV) infection is common in patients receiving hemodialysis. The uptake of antiviral therapy for these patients is limited in the era of interferon (IFN) plus ribavirin (RBV), probably because the sustained…
- Trial name
- NCT03420300
- Testing
- EBR/GZR
- Where
- 6 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.